Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study
Abstract
Background Standard treatments for pediatric acute gastroenteritis (AGE) have critical limitations in symptom control and medication adherence among young children. This study evaluated the efficacy and safety of Erxiekang Emplastra as adjunctive therapy for AGE in children aged 1 to 14 years. Methods This single-center retrospective cohort study reviewed electronic medical records of children hospitalized with AGE between January 2024 and March 2025. Eligible patients were categorized into an exposed group receiving Erxiekang Emplastra plus standard therapy and an unexposed group receiving standard therapy alone. The primary outcome was diarrhea duration; secondary outcomes included the 3-day Modified Vesikari Scale (MVS) and treatment-related adverse events. Multivariable linear regression was conducted to quantify the independent therapeutic benefits of the Erxiekang Emplastra. Results A total of 1,089 eligible patients were included, with 417 in the exposed group and 672 in the unexposed group. The exposed group had significantly shorter diarrhea duration (3.83 vs. 4.92 days, p < 0.01) and lower 3-day MVS (2.90 vs. 4.51, p < 0.01). Adjunctive Erxiekang Emplastra was independently associated with reduced diarrhea duration (β = –0.38, p < 0.01; R2 = 0.19) and lower 3-day MVS (β = –0.44, p < 0.01; R2 = 0.22). Only 1.44% of patients developed mild transient local reactions, with no severe adverse events reported. Conclusion Erxiekang Emplastra showed favorable tolerability…
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.